Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants

CC‐90001 selectively inhibits c‐Jun N‐terminal kinase (JNK), a stress‐activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC‐90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received oral CC‐90001 in a single dose (10–720 mg) or multiple doses (30–4...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Ying, Gaudy, Allison, Thomas, Michael, Reyes, Josephine, Burkhardt, Barbara, Horan, Gerald, Liu, Liangang, Chen, Jian, Ghosh, Atalanta, Carayannopoulos, Leonidas N., Tatosian, Daniel A., Palmisano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092235/
https://www.ncbi.nlm.nih.gov/pubmed/36256505
http://dx.doi.org/10.1002/cpdd.1178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092235/
https://www.ncbi.nlm.nih.gov/pubmed/36256505
http://dx.doi.org/10.1002/cpdd.1178

Ejemplares similares